Penserra Capital Management LLC Immatics N.V. Transaction History

Penserra Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.0 - $9.37 $60 - $93	-10 Reduced 0.46%	2,175 $18,000
Q1 2022 May 13, 2022	SELL	$6.64 - $12.85 $3,877 - $7,504	-584 Reduced 21.09%	2,185 $17,000
Q4 2021 Feb 15, 2022	SELL	$10.81 - $14.38 $17,523 - $23,309	-1,621 Reduced 36.92%	2,769 $37,000
Q3 2021 Nov 15, 2021	SELL	$11.58 - $15.46 $64,037 - $85,493	-5,530 Reduced 55.75%	4,390 $57,000
Q2 2021 Aug 12, 2021	SELL	$10.43 - $12.81 $41,594 - $51,086	-3,988 Reduced 28.67%	9,920 $115,000
Q1 2021 May 13, 2021	SELL	$10.24 - $14.6 $308,623 - $440,029	-30,139 Reduced 68.42%	13,908 $155,000
Q4 2020 Feb 12, 2021	BUY	$9.67 - $12.05 $371,937 - $463,479	38,463 Added 688.81%	44,047 $475,000
Q3 2020 Nov 13, 2020	BUY	$8.73 - $15.15 $48,748 - $84,597	5,584 New	5,584 $63,000

76.6M

571K

210K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.